- Home
- IREN vs MRNA Comparison
IREN vs MRNA Comparison
Compare IREN & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IREN
- MRNA
- Stock Information
- Founded
- IREN 2018
- MRNA 2010
- Country
- IREN Australia
- MRNA United States
- Employees
- IREN N/A
- MRNA N/A
- Industry
- IREN EDP Services
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IREN Technology
- MRNA Health Care
- Exchange
- IREN Nasdaq
- MRNA Nasdaq
- Market Cap
- IREN 9.9B
- MRNA 9.8B
- IPO Year
- IREN 2021
- MRNA 2018
- Fundamental
- Price
- IREN $68.59
- MRNA $24.14
- Analyst Decision
- IREN Buy
- MRNA Hold
- Analyst Count
- IREN 10
- MRNA 15
- Target Price
- IREN $65.63
- MRNA $37.15
- AVG Volume (30 Days)
- IREN 45.1M
- MRNA 11.1M
- Earning Date
- IREN 11-06-2025
- MRNA 11-06-2025
- Dividend Yield
- IREN N/A
- MRNA N/A
- EPS Growth
- IREN N/A
- MRNA N/A
- EPS
- IREN 0.39
- MRNA N/A
- Revenue
- IREN $501,023,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- IREN $136.32
- MRNA N/A
- Revenue Next Year
- IREN $48.31
- MRNA $11.12
- P/E Ratio
- IREN $173.63
- MRNA N/A
- Revenue Growth
- IREN 167.65
- MRNA N/A
- 52 Week Low
- IREN $5.13
- MRNA $23.15
- 52 Week High
- IREN $75.73
- MRNA $56.70
- Technical
- Relative Strength Index (RSI)
- IREN 64.14
- MRNA 41.44
- Support Level
- IREN $57.28
- MRNA $24.25
- Resistance Level
- IREN $75.73
- MRNA $29.20
- Average True Range (ATR)
- IREN 6.14
- MRNA 1.48
- MACD
- IREN -0.27
- MRNA -0.25
- Stochastic Oscillator
- IREN 74.06
- MRNA 0.00
About IREN Iris Energy Limited
IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy. Bitcoin mining operations generate revenue by earning Bitcoin through a combination of Block rewards and transaction fees from the operation of its Bitcoin miners and exchanging these Bitcoin for fiat currencies such as USD or CAD.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.